Impact of Procalcitonin (PCT)-Guided Antibiotic Therapy on Mortality in Critically Ill Patients: A Systematic Review and Meta-Analysis of 18 Randomized Controlled Trials

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.

Citation

Published Version
doi:10.1093/ofid/ofx163.845

Citable link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:34493120

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Background. Brucellosis is still endemic in many developing countries and frequently leads to misdiagnosis and treatment delays. Indirect inflammatory markers such as mean platelet volume (MPV), platelet distribution width (PDW), red cell distribution width (RDW), neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) have been identified as markers of inflammation. The present study aimed to evaluate and compare the levels of these markers for prognostic purposes and to assess the correlation of C-reactive protein (CRP) with brucellosis in adults and children.

Methods. The study included 137 adults and 41 age- and gender-matched healthy controls, as well 71 children and 81 age- and gender-matched healthy controls. Hematological parameters and CRP were retrospectively recorded and compared between the adult and pediatric patients.

Results. The mean age of the adult patients (54% female) was 43.1 ± 15.4 years, whereas the mean age of the pediatric patients (50.2% male) was 9.5 ± 3.6 years. Significantly higher lymphocyte count, and lower neutrophil count, platelet count, RDW, MPV, NLR and PLR values were found in adult brucellosis patients compared with their healthy subjects, whereas higher lymphocyte count, PDW and lower neutrophil count, platelet count, MPV, NLR and PLR values were observed in pediatric brucellosis patients compared with the control subjects. Significantly higher neutrophil count (p = 0.019) and NLR (p < 0.001) were found in adult patients compared with the pediatric patients. Positive correlation was found between CRP and NLR (R² = 0.652, p = 0.011), PLR (R² = 0.661, p = 0.016) in adult patients.

Conclusion. Based on our findings, we consider that the use of complementary indirect markers such as MPV, NLR, PLR and RDW together with the CRP test – which is used concomitantly with serological diagnostic tests in situations where brucellosis is suspected – might be helpful in the diagnosis and follow-up of brucellosis, as well as in the evaluation of complications and response to therapy, in both adult and pediatric brucellosis patients.

Disclosures. All authors: No reported disclosures.

1148. Impact of Procalcitonin (PCT)-Guided Antibiotic Therapy on Mortality in Critically Ill Patients: A Systematic Review and Meta-Analysis of 18 Randomized Controlled Trials

Dominique Pepper, MD MBCch; Junfeng Sun, PhD; Chau Rhee, MD, MPh; Judith Welsh, BSN; John H. Powers III, MD; Robert L. Danner, MD; and Sameer Kadi, MD

Critical Care Medicine Department, National Institutes of Health, Bethesda, MD; Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts; National Institutes of Health Library, National Institutes of Health, Bethesda, Maryland; Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc., NCI Campus at Frederick; Frederick, Maryland. Critical Care Medicine Department, National Institutes of Health Clinical Center, Bethesda, Maryland

Session: 144. Diagnostics: Biomarkers
Friday, October 6, 2017: 12:30 PM

Background. Procalcitonin (PCT)-guided antibiotic therapy has been shown to reduce antibiotic use in critically ill patients with suspected or proven infection, but its impact on mortality remains uncertain. Our meta-analysis examines the effect of PCT-guided antibiotic therapy on survival in critically ill patients.

Methods. We searched PubMed, the Cochrane Library, Scopus, Web of Science, EMBASE and clinicaltrials.gov electronic databases up to October 2016. The meta-analysis was restricted to randomized controlled trials (RCTs) of critically ill patients receiving PCT-guided antibiotic treatment and reporting survival or antibiotic duration. Study quality was assessed using the Cochrane risk of bias tool. Two reviewers conducted all review stages independently, and a third reviewer adjudicated any differences. Data was pooled using random-effects meta-analysis.

Results. Of the 18 RCTs selected (n = 5,183 patients; Table), 17 assessed mortality and 15 assessed antibiotic duration. NLR; it scored ≥3 and 10 scored ≥2 out of 6 on the risk of bias assessment. Compared with controls, PCT-guided antibiotic treatment was associated with a significant reduction in mortality (20.7% vs. 23.0%; risk ratio [RR] 0.90 [95% CI 0.81–0.99], I²=0%; Figure 1). Survival benefit was retained in the RCT subset with a lower risk of bias (score ≥3; RR 0.87 [95% CI, 0.77–0.98], I²=0%; Figure 2) but not with higher risk (score ≤2; RR 0.98 [95% CI, 0.81–1.0], I²=100%). Our analysis of the effect of PCT-guided antibiotic therapy on antibiotic duration displayed significant heterogeneity (I² = 61.2%, P = 0.004), which precluded reporting on aggregate effect. Important limitations were: single previously conducted double-blind (all studies) and variable protocol non-adequence and timeframes examined for mortality.

Conclusion. In a meta-analysis of RCTs of critically ill patients with suspected or proven infection, PCT-guided antibiotic treatment was associated with a significant reduction in mortality. The observed survival benefit was weighted towards RCTs of relatively higher quality. However, the plausibility of this finding, as well as the impact of protocol non-adequence on outcome needs further study.

Disclosures. All authors: No reported disclosures.

1149. Serial Procalcitonin Levels Correlate with Microbial Etiology in Hospitalized Patients with Lower Respiratory Tract Infections

Kfir Oved, PhD; Eran Eden, PhD; Chantal Van Houten, MD; Tanya Gottlieb, MD; Roy Navon, MSc; Asi Cohen, PhD; Olga Boico, PhD; Meital Paz, BSc.; Liat Etshtein, MD; Gali Kronenberg, MSc; Tom Friedman, MD; Ellen Bamberger, MD; Irina Chistyakov, MD; Israel Potsman, MD, FIDSA; Michal Stein, MD; Adi Klein, MD; Alain Gervaix, MD; Isac Gruge, MD; and Louis Bont, MD, PhD; McMed Diagnostics, Tirat Carmel, Israel; Division of Paediatric Immunology and Infectious Diseases, University Medical Centre Utrecht, Utrecht, Netherlands; Rambam Health Care Campus, Haifa, Israel; Bnai Zion Medical Center, Haifa, Israel; Rapport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel; Department of Pediatrics, Bnai Zion Medical Center, Haifa, Israel; Infectious Diseases, Bnai Zion Med. Ctr., Haifa, Israel; Infectious Disease Unit, Hilf Medical Center, Haifa, Israel; Department of Pediatrics, Medical Center, Heredia, Israel; Pediatric Emergency Division, Geneva University Hospitals and University of Geneva, Switzerland

Session: 144. Diagnostics: Biomarkers
Friday, October 6, 2017: 12:30 PM

Background. Bacterial and viral infections are often clinically indistinguishable, particularly in upper respiratory tract infections (URT), which leads to antibiotic misuse. A novel assay (ImmunoSpectr®) that integrates measurements of three host-response proteins (TRAIL, ip-10, CRP) was recently developed to assist in differentiation between bacterial and viral infections. We evaluated the assay performance in URTI patients and compared it with standard laboratory measures.

Methods. We performed a sub-analysis of 464 patients with clinical suspicion of URTI enrolled in three previously conducted multi-center clinical studies that evaluated the assay performance in patients with acute infections: ‘Curiosity’ study (NCT01917461), ‘Opportunity’ study (NCT01931254), and ‘Pathfinder’ study (NCT01911143). Comparator method was predetermined according to expert panel adjudication, which was performed by pooling the diagnostic performance was evaluated by comparing test and comparator method outcomes.

Results. A unanimous panel adjudication was reached for 61 bacterial (33%) and 241 viral (52%) patients (162 patients (35%) had an indeterminate diagnosis). The assay distinguished between bacterial and viral infected patients with a sensitivity of 93% (92%–95%), specificity 94% (93%–95%), accuracy 94% (92%–95%), PPV 95% (93%–96%), and NPV 91% (89%–93%) with a positive likelihood ratio of 16.7 (10.3–27.4) and negative likelihood ratio of 0.08 (0.04–0.17). No significant difference was found between NP and PPV of the assay compared to the comparator method (P = 0.95).

Conclusion. Serial procalcitonin levels during the early course of bacterial pneumonia reveal a difference between pneumococcal and other bacterial etiologies, and may have an adjunct role in guiding antibiotic choice and duration.

Disclosures. All authors: No reported disclosures.

Poster Abstracts • OFID 2017:4 (Suppl 1) • S351